Combination treatment for HER2-negative breast cancer brain metastasis

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study

This study is testing a new combination treatment for patients with HER2-negative breast cancer that has spread to the brain to see if it can help shrink tumors and improve survival.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: Beijing 302 Hospital (other)
• Drugs / interventions: Avelumab, Apatinib, Adebrelimab, Adebelizumab, camrelizumab, chemotherapy
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06418594 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effectiveness of a combination therapy using Adebrelimab, Apatinib, and Etoposide for patients with HER2-negative breast cancer that has metastasized to the brain. The study aims to evaluate the central nervous system objective response rate by targeting tumor growth through immunotherapy and chemotherapy. Participants will be closely monitored for their response to the treatment and overall survival. The trial is designed for patients who have experienced progression of their brain metastasis after previous treatments.

Who should consider this trial

Good fit: Ideal candidates include females aged 18 and older with confirmed HER2-negative breast cancer and measurable brain metastasis who have experienced treatment failure with prior therapies.

Not a fit: Patients with an urgent need for local treatment of brain metastasis or those with certain exclusion criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with HER2-negative breast cancer brain metastasis, potentially improving survival rates and quality of life.

How similar studies have performed: Other studies have shown promising results with similar combination therapies in treating brain metastases, indicating potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

* Female, aged ≥18 years
* Expected survival time ≥3 months.
* Histologically or cytologically confirmed HER2-negative (IHC 0 or 1+; or IHC 2+ ISH negative) locally recurrent or metastatic disease
* New brain metastasis or brain metastasis progression after treatment
* HR+ advanced breast cancer with prior CDK4/6 inhibitor treatment failure or the investigator deems unsuitable for CDK4/6 inhibitors
* At least one intracranial measurable lesion as defined by RECIST V1.1 criteria；
* ECOG PS 0-2；
* Patients must have the ability to swallow oral medication；
* Prior WBRT, stereotactic radiosurgery, and surgical resection are allowed；
* Organ function levels are basically normal, and the investigator believes that the study drug can be applied：
* Voluntarily join this study, sign the informed consent, have good compliance, and are willing to cooperate with follow-up

Exclusion Criteria:

* Urgent need for local treatment of brain metastasis
* Immunohistochemistry HER2 positive (IHC 3 or IHC 2 ISH amplification)
* Previously treated with Apatinib, Avelumab, or VP-16；
* Severe dysfunction of important organs such as the heart, liver, or kidneys；
* Inability to swallow, chronic diarrhea, and intestinal obstruction, with multiple factors affecting drug administration and absorption；
* Participants diagnosed with any other malignant tumor within 5 years before this study, excluding non-melanoma skin cancer that has undergone radical treatment. Basal cell or squamous cell skin cancer or cervical carcinoma in situ and thyroid papillary carcinoma。
* Patients who allergy to any component of the drugs in this protocol; patients with history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation
* History of any cardiac disease, including: (1) arrhythmia requiring medication or clinically significant; (2) myocardial infarction; (3) heart failure; (4) any other cardiac disease judged by the investigator to be unsuitable for participation in this trial, etc.
* Pregnant or lactation female patients; females of childbearing age with a positive baseline pregnancy test or unwilling to take effective contraceptive measures during the entire trial period；
* According to the investigator's judgment, there are severe accompanying diseases that endanger the patient's safety or affect the completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, etc.).

Where this trial is running

Beijing, Beijing Municipality

• The Fifth Medical Center of PLA General Hospital — Beijing, Beijing Municipality, China (RECRUITING)

Study contacts

• Study coordinator: Jinmei Zhou, Doctor

Conditions: HER2-negative Breast Cancer Brain Metastases